2011 FDA Guideline on Process Validation

This presentation will articulate what has changed and how we need to react. Validation as derived from industry practice has a new spin.

Louis Angelucci
Instructor:
Louis Angelucci
Duration:
60 Minutes
Product Id:
501296
Access:
6 months

More Trainings by this Expert

Price Details
$190 Recorded
$390 Corporate Recorded
Price Detail Options
Overview:

The FDA in 2011 instituted its latest interpretation. Many have not chosen to take it seriously or change their business model. The paradigm has shifted and this presentation will articulate what has changed and how we need to react. Validation as derived from industry practice has a new spin. This presentation will take you through that development and demonstrate how some in the industry have reacted to the new expectations.

Why should you Attend: This is a topic very near and dear to those who are involved with qualification and validation. Of all the topics regarding compliance this subject area has to be the most re-invented. Those in attendance will hear how to approach the topic and what some companies are currently doing to meet the expectation. If you are new to the topic or just want to learn more regarding this evolving area of compliance then consider attending this session.

Areas Covered in the Session:

  • What it means
  • What it says
  • What is in and what is out
  • Comparison of what has changed
  • PPQ1 and PPQ2
  • What is PV
  • What is Qualification
  • ASTM 2500
  • European Interpretation
  • Inconsistencies
  • Hybrid Compliance
  • Hyper-care
  • The 3X rule
  • What is validation and what is not

Who Will Benefit:
  • Compliance Personnel
  • QA Personnel
  • Validation Personnel


Speaker Profile
Louis Angelucci is a pharmaceutical professional and Certified Quality Engineer with over 20 years of experience in Quality Assurance, Quality Control, Validation, consent decree remediation as well as cGMP Compliance in the Medical Device and Pharmaceutical industries.

Lou has worked for several well know companies inclusive of Johnson & Johnson, Bristol-Meyer Squibb, Pfizer, Schering Plough and Merck. This work experience was acquired either as a direct employee or as a contracting consultant while employed at Foster Wheeler and Aker Kvaerner. As a consultant Lou has worked at various project locations both domestically and overseas.

Lou is a member of the IVT board of Directors and has been a contributing speaker to IVT since the organization's early beginnings. He has published numerous articles on the subjects of Validation and compliance and has been a speaker to industry groups such as ISPE, IDE, PDA and ASQ.

Lou is currently employed by Validant a Quality, Regulatory and Engineering consulting firm with expertise in biotechnology, pharmaceutical and medical device industries. Lou is a Quality Systems Consultant specializing in Validation and Quality System Consent Decree administration and remediation.


You Recently Viewed